Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C6H10O7.C4H6N4O3 |
| Molecular Weight | 352.2548 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | C4H6N4O3 |
SHOW SMILES / InChI
SMILES
NC(=O)NC1NC(=O)NC1=O.O[C@@H](C=O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O
InChI
InChIKey=HXVHQYMITPIBOD-RMTXHFLUSA-N
InChI=1S/C6H10O7.C4H6N4O3/c7-1-2(8)3(9)4(10)5(11)6(12)13;5-3(10)6-1-2(9)8-4(11)7-1/h1-5,8-11H,(H,12,13);1H,(H3,5,6,10)(H2,7,8,9,11)/t2-,3+,4+,5-;/m0./s1
DescriptionSources: http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfhttp://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883Curator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
Sources: http://biotechnologia.pl/uploads/biotechnologia/product/leaflet/156476/info_20ALCLOXA.pdfhttp://www.rad-ar.or.jp/siori/english/kekka_plain.cgi?n=34714 | https://www.ncbi.nlm.nih.gov/pubmed/26620883
Curator's Comment: description was created based on several sources, including:
http://tri-k.com/acloxa
Aldioxa is the generic name for the metal complex, dihydroxyaluminum allantoinate, which is hydrolyzed to allantoin and aluminium hydrate at the gastric mucosa. Aldioxa was approved in Japan to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. It was discovered, that aldioxa ameliorates delayed gastric emptying through its antagonistic activity on the α-2 adrenergic receptor. The most commonly reported adverse reactions include constipation.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1867 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | BODYGLIDE FOR HER Approved Usehelps prevent and helps relieve chafed, chapped or cracked skin. helps protect from the drying effects of wind and cold weather. temporarily protects minor cuts, scrapes, burns. Launch Date2009 |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
|||
| Primary | Unknown Approved Useprotects gastric / duodenal tissue mucosa and helps repair, thus improving gastric / duodenal ulcer and gastritis. It is usually used to improve subjective symptoms or objective of gastric/duodenal ulcer and gastritis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.43 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
30 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9131540/ |
10 mg/kg 3 times / day steady-state, oral dose: 10 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: |
ALLANTOIN plasma | Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Pharmacological study of dihydroxyaluminum allantoinate and chlorhydroxyaluminum allantoinate. I. Toxicity]. | 1962 Jul-Aug |
|
| [Evaluation of the anti-ulcer drugs using image analysis technology: effect of aldioxa containing preparation on the experimental gastric ulcer in rats]. | 1989 Nov |
|
| [The effect of aldioxa on the formation of gastritis induced with sodium hydroxide]. | 1990 Nov |
|
| [Acidified aspirin-induced gastric lesion in rats with hepatic cirrhosis produced by N-nitrosodiethylamine or carbon tetrachloride. Effect of aldioxa on gastric lesions]. | 1994 Mar |
|
| Aldioxa improves delayed gastric emptying and impaired gastric compliance, pathophysiologic mechanisms of functional dyspepsia. | 2015 Dec 1 |
Sample Use Guides
Antiperspirants, deodorants: Creams, spray, lossions: 0.25-0.5%
Baby products: creams; powders: 0.2-0.5%
Route of Administration:
Topical
In vitro Alcloxa inhibited formation and bacterial decomposition of pulverized human epidermal scales. The scales were obtained from patient with exfoliative dermatitis, characterized by a great deal of exudation. The scales were were pulverized in a Wiley mill, defatted with ether and suspended in a 0,2% Alcloxa solution.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M25U72FT59
Created by
admin on Sat Dec 16 00:49:31 GMT 2023 , Edited by admin on Sat Dec 16 00:49:31 GMT 2023
|
PRIMARY | |||
|
87319941
Created by
admin on Sat Dec 16 00:49:31 GMT 2023 , Edited by admin on Sat Dec 16 00:49:31 GMT 2023
|
PRIMARY | |||
|
DTXSID00199206
Created by
admin on Sat Dec 16 00:49:31 GMT 2023 , Edited by admin on Sat Dec 16 00:49:31 GMT 2023
|
PRIMARY | |||
|
5119-24-4
Created by
admin on Sat Dec 16 00:49:31 GMT 2023 , Edited by admin on Sat Dec 16 00:49:31 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
